Navigation Links
'Fertilizing' bone marrow helps answer why some cancers spread to bones
Date:5/14/2012

ANN ARBOR, Mich.Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily.

The findings provide valuable insight as to why some cancers metastasize to bone, and could eventually result in new metastasis-prevention drugs, said Laurie McCauley, professor in the Department of Periodontics and Oral Medicine at the University of Michigan School of Dentistry and principal investigator on the study.

The really good news is that researchers reversed the tumor-friendly effect of the drug, called cyclophosphamide, by inhibiting another cell-communicating protein in the bone marrow, called CCL2.

"This work is early and still at the pre-clinical level," said McCauley, who also has an appointment in the Department of Pathology at the U-M Health System. "However, the biggest potential impact is in metastasis preventive strategies.

"If we better understood the specific mediators, or conditions, in the bone marrow that support tumors, we could develop more effective therapeutics to prevent local cancers from spreading and hence reduce metastasis to the bone."

The study highlights the potential for the bone marrow to provide the right environment for tumors to metastasize, said Serk In Park, first author and a postdoctoral fellow in McCauley's lab. Many cancers, such as prostate and breast cancer, are fond of spreading, or metastasizing, to bones.

Researchers administered the chemotherapy drug cyclophosphamide experimentally to manipulate the environment inside the bone marrow prior to exposing experimental tumors. Cyclophosphamide therapy is used in certain cancers to slow cell growth, and McCauley's group experimented with its use in a pre-metastatic mode using a prostate cancer model.

While effective at attacking tumor cells, a side effect of cyclophosphamide (and many other chemotherapy drugs) is that it suppresses certain bone marrow cells that help the immune system and increases some harmful cells. Researchers hypothesized correctly that the drug would make the bone marrow more tumor-friendly.


'/>"/>

Contact: Laura Bailey
baileylm@umich.edu
734-647-1848
University of Michigan
Source:Eurekalert

Related medicine news :

1. New Drug May Help Fight Rare Bone Marrow Disorder
2. Survival rates for pediatric bone marrow transplants top in nation
3. Bone marrow and blood stem cell transplant survival rates equal, when donor is unrelated to patient
4. Biomarker detects graft-versus-host-disease in cancer patients after bone marrow transplant
5. Bone marrow cells migrate to tumors and can slow their growth
6. New half-match bone marrow transplant procedure yields promising outcomes for cancer patients
7. Bone marrow transplantation may increase cancer resistance in patients
8. Stem cell mobilization therapy found to be safe for bone marrow donors
9. Bone marrow transplant survival more than doubles for young high-risk leukemia patients
10. Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy
11. Study reveals origins of a cancer affecting the blood and bone marrow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Students interested ... Tissue Donation Awareness Scholarship competition., The winner will earn a $1,000 scholarship and have ... competition begins Feb. 1, and the deadline is May 31, with the winner announced ...
(Date:1/19/2017)... Pittsburgh, PA (PRWEB) , ... January 19, 2017 , ... ... the experience of patients who seek access to the Network’s programs and services in ... requesting primary or specialty care appointments will be offered one for that same afternoon. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... agency which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating ... lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second ... Associates of Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. ... have each been chosen by their peers for the 2017 list based on ...
(Date:1/19/2017)... ... ... The 21st Century Cures Act’s Impact on Medical Devices:, What You Need ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do manufacturers ... year? , The passage of the act means devicemakers will be scrambling to meet ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Accuray Incorporated (Nasdaq: ... and TomoTherapy® Systems continue to set the bar for ... highest composite overall user satisfaction rating among radiation treatment ... 2016 MD Buyline Market Intelligence Briefing™. The most recent ... composite ratings among industry peers for 11 of the ...
(Date:1/19/2017)... 2017 Shire plc (LSE: SHP, ... Food and Drug Administration (FDA) has acknowledged receipt of ... (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine salts ... treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected ... 2017, the designated Prescription Drug User Fee Act (PDUFA) ...
(Date:1/19/2017)... -- The global  pacemaker market  is expected to reach USD 12.3 ... The heightening prevalence of cardiac conditions coupled with the availability of medical coverage ... technological enhancements in these devices are supporting the expansion of this vertical. ... ... Grand View Research Logo ...
Breaking Medicine Technology: